Positions

Overview

  • Dr. Krontiras, a breast surgical oncologist, is the Medical Director of the UAB Multidisciplinary Breast Clinic, a clinic in which medical oncologists, surgeons and radiation oncologists work together to see approximately 450 new breast cancer cases each year. She is the Co-Director of the Lynne Cohen Preventive Care Program for Women's Cancers at UAB and the Co-Director of the Breast Cancer Prevention and Risk Assessment Clinic. In her role as Assistant Chief Medical Officer for Ambulatory Quality and Patient Safety for UAB Medicine, she participates in quality improvement and quality assurance activities related to delivery of high quality and cost-effective care, including analysis and regular review of ambulatory quality outcomes, and data and development of improvements in clinical and operational processes.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 The impact of breast lumpectomy tray utilization on cost savingsJournal of Surgical Research.  233:32-35. 2019
    2018 Treatment patterns for ductal carcinoma in situ with close or positive mastectomy marginsJournal of Surgical Research.  231:36-42. 2018
    2018 Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely® CampaignAnnals of Surgical Oncology.  25:2795-2800. 2018
    2018 A Structured Compensation Plan Improves But Does Not Erase the Sex Pay Gap in Surgery.Annals of Surgery.  268:442-448. 2018
    2018 Breast Cancer Genetics and Indications for Prophylactic MastectomySurgical Clinics of North America.  98:677-685. 2018
    2018 Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient EncountersAnnals of Surgical Oncology.  25:501-511. 2018
    2017 NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancerClinical Cancer Research.  23:4055-4065. 2017
    2016 Translation of a tissue-selective rexinoid, UAB30, to the clinic for breast cancer preventionCurrent Topics in Medicinal Chemistry.  16. 2016
    2016 Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely ®InitiativeAnnals of Surgical Oncology.  23:3112-3118. 2016
    2016 Exploring effects of presurgical weight loss among women with stage 0-II breast cancer: Protocol for a randomised controlled feasibility trialBMJ Open.  6. 2016
    2016 Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivorsSupportive Care in Cancer.  24:3285-3293. 2016
    2016 Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013Journal of Clinical Oncology.  34:2359-2365. 2016
    2015 Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivorsBreast Cancer Research and Treatment.  154:329-337. 2015
    2015 Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivorsBreast Cancer Research and Treatment2015
    2015 Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary CancersJournal of Medicinal Chemistry.  58:7763-7774. 2015
    2015 Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: A behavioral weight loss intervention in overweight or obese breast cancer survivorsJournal of Clinical Oncology.  33:3169-3176. 2015
    2015 Breast cancer risk reduction, version 2.2015 clinical practice guidelines in oncology clinical practice guidelines in oncologyJournal of the National Comprehensive Cancer Network.  13:880-915. 2015
    2015 TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancerClinical Cancer Research.  21:2722-2729. 2015
    2014 S-(-)equol producing status not associated with breast cancer risk among low isoflavone-consuming US postmenopausal women undergoing a physician-recommended breast biopsyNutrition Research.  34:116-125. 2014
    2014 Socioeconomic disparities in breast cancer treatment among older womenJournal of Women's Health.  23:335-341. 2014
    2014 Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657)Annals of Surgical Oncology.  21:2889-2896. 2014
    2014 What is a clear margin in breast conserving cancer surgery?Current Treatment Options in Oncology.  15:79-85. 2014
    2013 Comparative evaluation of [99mTc]tilmanocept for sentinel lymph node mapping in breast cancer patients: Results of two phase 3 trialsAnnals of Surgical Oncology.  20:2590-2599. 2013
    2013 Harvest for health gardening intervention feasibility study in cancer survivorsActa Oncologica.  52:1110-1118. 2013
    2013 Reducing breast cancer recurrence with weight loss, a vanguard trial: The Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) TrialControlled Clinical Trials.  34:282-295. 2013
    2013 How do i screen patients for breast cancer?Current Treatment Options in Oncology.  14:88-96. 2013
    2012 LEAP: Lead, Excel, Achieve, Perform: A Report on the UHC Annual Conference 2011American Journal of Medical Quality.  27. 2012
    2012 Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657Journal of Clinical Oncology.  30:3242-3249. 2012
    2012 Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Breast Cancer Research and Treatment.  132:1049-1062. 2012
    2012 Locally advanced breast cancers are more likely to present as interval cancers: Results from the I-SPY 1 TRIAL (CALGB 150007/150012, acrin 6657, interSPORE trial)Breast Cancer Research and Treatment.  132:871-879. 2012
    2011 An update on the dosimetric analysis of concurrent radiation therapy and trastuzumab on early cardiac events.Journal of Clinical Oncology.  29:121. 2011
    2011 Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer.Journal of Clinical Oncology.  29:e11048. 2011
    2011 Image-guided methods for biopsy of suspicious breast lesionsJournal of Surgical Oncology.  103:299-305. 2011
    2011 Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapyClinical Breast Cancer.  11:312-319. 2011
    2010 A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteersCancer Prevention Research.  3:1565-1570. 2010
    2010 Breast cancer risk reductionJournal of the National Comprehensive Cancer Network.  8:1112-1146. 2010
    2010 Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancerClinical Breast Cancer.  10:275-280. 2010
    2010 Less-than-standard treatment in rectal cancer patients: Which patients are at risk?Journal of the National Medical Association.  102:190-198. 2010
    2009 Beta-human chorionic gonadotropin production associated with phyllodes tumor of the breast: An unusual paraneoplastic phenomenonBreast Journal.  15:527-530. 2009
    2009 DiscussionAmerican Surgeon.  75:784. 2009
    2009 Specimen radiographs assist in identifying and assessing resection margins of occult breast carcinomasBreast Journal.  15:521-523. 2009
    2009 Breast cancer screening and diagnosis: Clinical practice guidelines in oncology™Journal of the National Comprehensive Cancer Network.  7:1060-1096. 2009
    2008 The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and Her2/neu status in breast carcinomaBreast Journal.  14:141-146. 2008
    2008 Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancersJournal of Clinical Oncology.  26:897-906. 2008
    2006 DiscussionAmerican Surgeon.  72:1194-1195. 2006
    2006 Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer.Journal of Clinical Oncology.  24:10622. 2006
    2006 Breast cancer screening and diagnosis: Clinical practice guidelines in oncology™Journal of the National Comprehensive Cancer Network.  4:480-508. 2006
    2004 Nuclear Localization of KLF4 Is Associated with An Aggressive Phenotype in Early-Stage Breast CancerClinical Cancer Research.  10:2709-2719. 2004
    2003 Axillary Lymph Node Status, but Not Tumor Size, Predicts Locoregional Recurrence and Overall Survival after Mastectomy for Breast CancerAnnals of Surgery.  237:732-739. 2003
    2003 When is sentinel node biopsy for breast cancer contraindicated?Surgical Oncology.  12:207-210. 2003
    2001 Molecular biomarkers for breast cancer prognosis: Coexpression of c-erbB-2 and p53Annals of Surgery.  233:630-638. 2001
    2001 Options for management of the axillary lymph nodes in breast cancerBreast.  10:62-68. 2001
    2001 Who should not receive chemotherapy? Data from American databases and trials.JNCI Monographs.  109-113. 2001
    1999 Transforming growth factor α (TGF-α) expression in dysplastic oral leukoplakia: Modulation by 13-cis retinoic acidHead & neck surgery.  21:566-573. 1999
    1999 Fatty acid synthase expression is increased in neoplastic lesions of the oral tongueHead & neck surgery.  21:325-329. 1999
    1999 T1 and t2 squamous cell carcinoma of the oral tongue: Prognostic factors and the role of elective lymph node dissectionHead & neck surgery.  21:124-130. 1999

    Chapter

    Year Title Altmetric
    2018 Diagnostic approach to breast abnormalities.  610-623. 2018
    2012 Diagnostic approach to breast abnormalities 2012

    Research Overview

  • Dr. Krontiras is a fellowship trained breast surgical oncologist with primary research interests in prevention and risk assessment of breast cancer, quality in cancer care, and outcomes of breast cancer treatment.

    Keywords - breast cancer, chemoprvention
  • Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 1994
  • UAB Hospital, Internship 1995
  • UAB Hospital, Residency 2000
  • Northwestern Memorial Hospital, Postdoctoral Fellowship 2001
  • Full Name

  • Helen Krontiras
  • Fax

  • 205-975-5971